Laser-Assisted Disinfection With and Without Photobiomodulation in Regenerative Endodontic Procedures for Necrotic Mature Teeth (LASER)

November 6, 2026 updated by: mohamed khalid moselhy, Future University in Egypt

Radiographic and Clinical Evaluation of Regenerative Endodontic Procedures in Necrotic Mature Teeth With Apical Periodontitis Using Laser-Assisted Disinfection With and Without Adjunctive Photobiomodulation: A Three-Arm Randomized Clinical Trial

This study will compare three ways of treating adult teeth with a dead nerve (pulp) and an infection at the root tip. All three groups receive a regenerative endodontic procedure, which aims to help healthy tissue grow back inside the tooth. The groups differ in how the root canal is cleaned: (1) standard cleaning without a laser, (2) standard cleaning plus a diode laser to help disinfect the canal, or (3) standard cleaning plus the diode laser plus a single session of low-level light therapy (photobiomodulation) applied over the gum to support healing. Eighty-one patients aged 20 to 40 will be randomly placed into one of the three groups. Healing of the infection at the root tip will be measured with a 3D dental scan (CBCT) before treatment and 12 months later. Pain after treatment, painkiller use, and clinical signs such as swelling, tenderness, and gum pimples (sinus tract) will also be recorded. The study aims to find out whether adding laser treatment, with or without light therapy, improves healing.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Not yet recruiting

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Estimated)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
81

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Locations

  • Egypt
    • Cairo Governorate
      • Cairo, Cairo Governorate, Egypt
        • Future University in Egypt
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

20 years to 40 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

  • Good general health (ASA I or II)
  • Aged 20 to 40 years
  • Both sexes (male and female)
  • Single-rooted mature permanent tooth
  • Negative response to pulp sensibility testing (cold test)
  • Periapical radiolucency ranging from widening of the lamina dura/periodontal ligament space up to a periapical lesion less than 5 mm in diameter on CBCT
  • Restorable tooth with adequate remaining coronal structure and periodontal support
  • Patient agrees to participate and is able to sign informed consent

Exclusion Criteria:

  • Analgesic or antibiotic intake within 12 hours before the procedure
  • Immature teeth
  • Multi-rooted teeth
  • Periapical lesion 5 mm or more in diameter
  • Unrestorable teeth
  • Teeth with vertical root fracture, extensive internal or external resorption, grade 2 or 3 mobility, or non-restorable coronal destruction
  • Previous root canal treatment
  • Systemic conditions or medications affecting healing (for example uncontrolled diabetes, immunosuppression, bisphosphonate therapy)
  • Pregnant or lactating patients
  • Unable to understand the procedure, provide valid consent, or comply with follow-up
  • Known allergy to the irrigants or medicaments used in the protocol

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Active Comparator: REP's with no laser disinfection (control)

Regenerative endodontic procedure (REP) with conventional chemomechanical preparation only (2.5% sodium hypochlorite, passive ultrasonic activation, 17% EDTA, and sterile saline), followed by a calcium hydroxide intracanal dressing for 2 weeks. At the second visit: EDTA irrigation, induced apical bleeding to form a blood clot, collagen matrix, bioceramic putty barrier, and coronal seal. No laser is used.
Procedure: regenerative endodontic procedure (REP)

Two-visit regenerative endodontic procedure for necrotic mature teeth single root and single canal. Visit 1: access, working length determination, crown-down chemomechanical preparation with 2.5% sodium hypochlorite, passive ultrasonic activation, 17% EDTA, final saline rinse, and calcium hydroxide dressing for 2 weeks. Visit 2: 17% EDTA irrigation, induction of apical bleeding to form a blood clot, collagen matrix, bioceramic putty barrier, and coronal seal with glass ionomer. Performed identically in all three groups.
Experimental: REP's with laser-assisted disinfection, using adjunctive 810 nm diode laser irradiation.

Same REP protocol as the control group, with the addition of 810 nm diode laser disinfection at the first visit after the final saline rinse and before the calcium hydroxide dressing. Continuous wave mode, 1.5 W, 4 cycles of 5 seconds with 20-second intervals, using a 200 micrometer fiber placed 1 mm short of the working length and moved in a slow helical motion from apical to coronal. The canal is irrigated with 5 mL saline after each cycle. The second visit is identical to the control group.
Procedure: regenerative endodontic procedure (REP)

Two-visit regenerative endodontic procedure for necrotic mature teeth single root and single canal. Visit 1: access, working length determination, crown-down chemomechanical preparation with 2.5% sodium hypochlorite, passive ultrasonic activation, 17% EDTA, final saline rinse, and calcium hydroxide dressing for 2 weeks. Visit 2: 17% EDTA irrigation, induction of apical bleeding to form a blood clot, collagen matrix, bioceramic putty barrier, and coronal seal with glass ionomer. Performed identically in all three groups.

Device: 810 nm diode laser-assisted canal disinfection

Adjunctive canal disinfection at the first visit using an 810 nm diode laser (Elexxion, Germany), continuous wave, 1.5 W, 4 cycles of 5 seconds with 20-second intervals. A 200 micrometer fiber is placed 1 mm short of the working length and moved in a slow helical motion from apical to coronal at about 2 mm per second without touching the canal walls. The canal is irrigated with 5 mL sterile saline after each cycle.
Experimental: REP's with Laser-assisted disinfection and adjunctive photobiomodulation,

Same protocol as the laser-assisted disinfection group, plus a single session of transmucosal photobiomodulation (PBM) delivered at the second visit immediately after placement of the blood scaffold and coronal restoration. 810 nm diode laser, continuous wave, 200 mW, 8 mm tip in contact with the mucosa, applied at four sites per tooth (periapical and cervical regions on the buccal and lingual/palatal sides), 15 seconds and 3 J per site, for a total of 12 J per tooth.
Procedure: regenerative endodontic procedure (REP)

Two-visit regenerative endodontic procedure for necrotic mature teeth single root and single canal. Visit 1: access, working length determination, crown-down chemomechanical preparation with 2.5% sodium hypochlorite, passive ultrasonic activation, 17% EDTA, final saline rinse, and calcium hydroxide dressing for 2 weeks. Visit 2: 17% EDTA irrigation, induction of apical bleeding to form a blood clot, collagen matrix, bioceramic putty barrier, and coronal seal with glass ionomer. Performed identically in all three groups.

Device: 810 nm diode laser-assisted canal disinfection

Adjunctive canal disinfection at the first visit using an 810 nm diode laser (Elexxion, Germany), continuous wave, 1.5 W, 4 cycles of 5 seconds with 20-second intervals. A 200 micrometer fiber is placed 1 mm short of the working length and moved in a slow helical motion from apical to coronal at about 2 mm per second without touching the canal walls. The canal is irrigated with 5 mL sterile saline after each cycle.

Device: Photobiomodulation (810 nm diode laser)

Single session of transmucosal photobiomodulation at the second visit, immediately after placement of the blood scaffold and coronal restoration. 810 nm diode laser, continuous wave, 200 mW, 8 mm tip in contact with the mucosa. Four sites per tooth (periapical and cervical regions on the buccal and lingual/palatal sides), 15 seconds and 3 J per site, for a total of 12 J per tooth.

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Change in periapical lesion volume (mm3) measured on CBCT
Time Frame: baseline and 12 month

Periapical lesion volume in cubic millimeters measured on cone-beam computed tomography (CBCT) scans (field of view 50 x 50 mm, isometric voxel size 0.125 mm) by a blinded outcome assessor. Change from baseline to 12 months is compared among the three groups.
baseline and 12 month

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Postoperative pain intensity (Numeric Rating Scale)
Time Frame: Preoperative (baseline), 6 hours, 12 hours, 24 hours, 48 hours, and 72 hours

Patient-reported pain on the Numeric Rating Scale from 0 (no pain) to 10 (worst pain imaginable), collected by telephone by a blinded study coordinator.
Preoperative (baseline), 6 hours, 12 hours, 24 hours, 48 hours, and 72 hours
Postoperative analgesic intake
Time Frame: 6 hours, 12 hours, 24 hours, 48 hours, and 72 hours

Whether any analgesic was taken since the previous assessment, with the number of doses and dose per intake, recorded at each telephone contact.
6 hours, 12 hours, 24 hours, 48 hours, and 72 hours
Resolution of clinical signs and symptoms
Time Frame: Preoperative (baseline), second visit, 3 months, 6 months, and 12 months

Presence or absence of tenderness to percussion, tenderness to palpation, swelling, and sinus tract, and need for additional intervention, assessed by clinical examination by a blinded examiner.
Preoperative (baseline), second visit, 3 months, 6 months, and 12 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Future University in Egypt

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
December 1, 2026

Primary Completion (Estimated)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
December 1, 2027

Study Completion (Estimated)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
January 1, 2028

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
November 6, 2026

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 6, 2026

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
November 12, 2026

Study Record Updates

Last Update Posted (Actual)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
November 12, 2026

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
November 6, 2026

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
November 1, 2026

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • FUE-ENDO-REP-LASER-2026

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings